+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of Xanomeline and Trospium Chloride in children and adolescents with psychiatric disorders, including schizophrenia and autism-related irritability. This Phase 3, open-label study is sponsored by Karuna Therapeutics, Inc., a Bristol Myers Squibb company, aiming to understand how these drugs affect young patients over an extended period. Participants will receive specified doses of KarXT or the combination of KarXT and KarX-EC depending on their condition. The study is non-randomized and open-label, meaning all participants receive the study treatment without placebo comparison. The treatment period can last up to 56 weeks, during which the safety and side effects of the medications will be closely monitored. Throughout the study, participants will undergo regular assessments to monitor treatment emergent adverse events, serious adverse events, and special interest adverse events. Additional evaluations include symptom assessments using scales like the Columbia Suicide Severity Rating Scale, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, and Barnes-Akathisia Rating Scale. The study involves continuous safety monitoring and lasts up to 56 weeks, with follow-up to evaluate both tolerability and any psychiatric symptoms.

Age: 5Years - 17YearsAll GendersPhase 3
104 locations
T

Actively Recruiting

Researchers are studying how depression might influence the risk of developing Alzheimers disease AD by examining biological factors involved in both conditions. The study focuses on adults aged 60 and older with major depressive disorder and aims to understand whether treating depression affects Alzheimers-related biomarkers in the body. This research will use an FDA-approved antidepressant and compares its effects to a placebo in a controlled trial. Participants receive either escitalopram, a selective serotonin reuptake inhibitor SSRI, or a matching placebo. The medication starts at 10 mg daily for two weeks and may increase to 20 mg as tolerated, with the option to reduce the dose if needed. The treatment period lasts for eight weeks, during which changes in cerebrospinal fluid biomarkers related to Alzheimers disease and vascular dysfunction will be tracked alongside depression symptom scores. Throughout the study, participants will undergo physical and neurological exams, brain MRI scans, lumbar punctures, blood and urine tests, and cognitive assessments. Researchers will monitor changes in Alzheimers biomarkers and depression severity using specific scales at the start and end of the treatment period. The study includes safety monitoring and requires participants to be medically stable and cognitively unimpaired at the start. The total participation time covers the screening and an eight-week treatment phase.

Age: 60Years +All GendersPhase 4
2 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying the effects of hip bump manipulation HBM on healthy adults aged 18 to 45 years. The study aims to determine if HBM can improve hip internal rotation, increase the strength of hip external rotator muscles, reduce compensatory movements during hip flexion, and enhance landing mechanics. Although clinicians often use this high velocity low amplitude thrust technique, its benefits have not yet been proven through research. Participants will be randomly assigned to one of two groups one receiving the hip bump manipulation targeting the greater trochanter, and the other receiving a sham manipulation at the iliac crest. Both procedures are performed in a single session lasting about 20 minutes. This single-blinded trial compares the clinical outcomes between the active and sham groups. During the study visit, participants will undergo assessments before and after the intervention, including measures of hip external rotation strength, hip internal rotation range of motion, muscle activation via EMG, and bipodal landing mechanics. Additional measures include hip deviation with assisted hip flexion and external rotation range of motion. The entire evaluation occurs within one session, and the study concludes after these assessments.

Age: 18Years - 45YearsAll GendersPhase Not Applicable
1 location
I

Actively Recruiting

Researchers are evaluating an integrated harm reduction intervention IHRI compared to usual harm reduction HR services for Black and Latinx people who use drugs. The study aims to see if the IHRI improves the use of harm reduction services among this group, focusing on those who misuse opioids and possibly other substances. This health services research is sponsored by NYU Langone Health and uses a randomized parallel design. The IHRI program lasts 8 weeks, beginning with 4 weekly education lessons led by a care coordinator. The next 4 weeks involve identifying social vulnerabilities to guide referrals to social service organizations. Both groups receive mobile van outreach offering information on syringe exchange, clean user kits, naloxone use, and fentanyl strip distribution. The comparison group receives the usual harm reduction services without the IHRI education or personalized referrals. Participants will be monitored for attendance at harm reduction sessions up to week 8. Researchers will assess changes in drug use days, overdose risk scores, and quality of life from baseline to week 8. The study includes interviews confirming substance misuse per DSM-5 criteria and requires informed consent. The trial runs from November 2024 to March 2028, with primary outcomes measured by week 8 and completion expected by October 2027.

Age: 18Years +All GendersPhase Not Applicable
3 locations
E

Actively Recruiting

Researchers are evaluating lumateperone in a study involving children and teenagers aged 5 to 17 years who have irritability linked to Autism Spectrum Disorder ASD. This is a randomized, double-blind, placebo-controlled trial aimed at assessing the safety and effectiveness of lumateperone in this pediatric population. Diagnosis is confirmed using DSM-5-TR criteria and the K-SADS-PL assessment tool. Participants will be randomly assigned to one of three groups to receive either a high dose of lumateperone 42 mg, a low dose of lumateperone 21 mg, or a placebo. The treatment is taken orally once daily during a 6-week double-blind period. The study includes an initial screening phase lasting up to 14 days, and a safety follow-up visit occurs about one week after the last dose. During the study, participants will attend visits for screening, treatment, and safety follow-up. Researchers will evaluate irritability using the Aberrant Behavior Checklist - Irritability subscale at 6 weeks, along with the Clinical Global Impression-Severity scale. Safety monitoring will be conducted throughout, and total participation spans screening, 6 weeks of treatment, and a 1-week follow-up period.

Age: 5Years - 17YearsAll GendersPhase 3
41 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are investigating how cannabis use affects brain function in adolescents with depression. The study aims to understand the neural and psychiatric consequences of cannabis use, focusing on a wide range of depression severity and cannabis use patterns among participants aged 14 to 20 years. This research is sponsored by the University of Miami and includes both cannabis users and non-users with depressive symptoms or diagnoses. Participants will undergo neuroimaging using functional MRI fMRI at the start of the study and again at a one-year follow-up. Each fMRI session lasts about one hour and involves tasks that evaluate different aspects of reward circuitry activity in the brain. Following the imaging sessions, participants will be clinically followed for an additional year, with assessments continuing for up to three years total. During the study, participants will complete various evaluations including standardized questionnaires to measure depression severity, anhedonia loss of pleasure, and cannabis use frequency and quantity. Urine tests will be used to analyze cannabinoid metabolites. Researchers will monitor changes over time using tools such as the Beck Depression Inventory and the Montgomery-sberg Depression Rating Scale. Participants may also undergo clinical interviews and provide self-reports about symptoms and substance use. The total participation time may extend up to three years with periodic assessments.

Age: 14Years - 20YearsAll GendersPhase Not Applicable
2 locations
B

Actively Recruiting

Researchers are studying whether transcranial direct current stimulation tDCS, a non-invasive brain stimulation technique, can improve face emotion recognition in people with schizophrenia. The study focuses on applying tDCS over the brains motion processing area area MT to address difficulties in detecting facial motion, which contribute to social cognition challenges in schizophrenia. Brain activity will be measured using fMRI and EEG while participants view moving and dynamic face stimuli, comparing effects of active versus sham stimulation. Participants include 120 individuals with schizophrenia and 30 healthy controls. Those with schizophrenia will be randomly assigned to receive either active personalized, MR-guided cathodal HD-tDCS targeting area MT or sham stimulation that mimics the sensation without current flow. Each schizophrenia participant will undergo two sessions involving event-related potentials ERP and fMRI with up to 40 minutes of stimulation per session, spaced at least one week apart. Healthy controls will be assessed only at baseline. Participants will complete baseline assessments before randomization and then receive their assigned tDCS intervention during ERP and fMRI visits. Researchers will measure brain region activation related to motion and face emotion recognition, behavioral scores on motion discrimination, face emotion accuracy, and understanding mental states. The study includes comprehensive monitoring of brain responses and behavioral outcomes to evaluate the impact of tDCS over the study period ending in 2030.

Age: 18Years - 55YearsAll GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are studying if applying near infrared energy to the forehead can change blood flow in the brains of people with Major Depressive Disorder MDD. Near infrared energy is similar to light but invisible to the eye. This multi-center study involves about 60 adults with MDD undergoing MRI scans during transcranial photobiomodulation tPBM before and after treatment. Participants are randomly assigned to receive either active tPBM delivering near-infrared radiation at a dose of 291.7 mWcm2 for 333 seconds or a sham treatment with no radiation, over 16 sessions. All participants receive tPBM at the first and last visits. The treatment course spans multiple visits, with the active or sham treatment given from visit 2 to 18. During the study, participants undergo brain imaging and depression rating assessments at baseline and at various visits up to week 10. Researchers measure changes in cerebral blood flow and depression severity using the Montgomery-Asberg Depression Rating Scale. Safety and adherence are monitored throughout, with the study lasting about 10 weeks per participant.

Age: 18Years - 65YearsAll GendersPhase Not Applicable
3 locations